Gabe Sonke, Professor of Clinical Oncology at the Netherlands Cancer Institute, shared a post on LinkedIn:
“Today at ESMO2025, Noor Wortelboer presented the overall survival results of the SONIA trial, evaluating the optimal sequencing of CDK4/6 inhibitors in ER+/HER2- advanced breast cancer.
The data demonstrated very similar overall survival with CDK4/6 inhibitor use in the first vs. second line:
• Hazard Ratio: 0.91 (95% CI: 0.77–1.07)
• Median OS: 47.9 vs. 48.1 months
These outcomes reflect a real-world patient population that was included in SONIA
In subgroup analyses, no OS benefit was observed for first-line vs. second-line use with either palbociclib or ribociclib, suggesting that ribociclib’s established OS benefit can be achieved in both treatment lines.
A post-hoc analysis indicated that pre-menopausal patients may derive greater benefit from first-line CDK4/6 inhibitor use.
These findings provide valuable insights for optimizing treatment sequencing in ER+/HER2- advanced breast cancer — with implications for patients across low-, middle-, and high-income countries.”
You can also read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
ESMO 2025 Day 4 Highlights Not to Miss
